| [30] |
莫均荣，张振辉，陈美婷, 等. 基于GEO芯片和生物信息学分析构建脓毒症相关ceRNA网络[J]. 中华危重病急救医学,2021,33(4):427-432.
|
| [1] |
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3)[J]. J Am Med Assoc,2016,315(8):801-810.
|
| [2] |
Rubio I, Osuchowski MF, Shankar-Hari M, et al. Current gaps in sepsis immunology: New opportunities for translational research[J]. Lancet Infect Dis,2019,19(12):E422-E436.
|
| [3] |
Fleischmann C, Scherag A, Adhikari NKJ, et al. Assessment of global incidence and mortality of hospital-treated sepsis[J]. Am J Respir Crit Care Med,2016,193(3):259-272.
|
| [4] |
Xin P, Xu X, Deng C, et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases[J]. Int Immunopharmacol, 2020,80:106210.
|
| [5] |
Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK/STAT pathway[J]. Protein Sci,2018,27(12): 1984-2009.
|
| [6] |
Villarino AV, Kanno Y, O’shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system[J]. Nat Immunol,2017,18(4):374-384.
|
| [7] |
Amini-Farsani Z, Yadollahi-Farsani M, Arab S, et al. Prediction and analysis of micrornas involved in COVID-19 inflammatory processes associated with the NF-kB and JAK/STAT signaling pathways[J]. Int Immunopharmacol,2021,100:108071.
|
| [8] |
Tzeng HT, Chyuan IT, Lai JH. Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential[J]. Biochem Pharmacol,2021,193:114760.
|
| [9] |
Stark R, Hartung A, Zehn D, et al. IL-12-mediated STAT4 signaling and TCR signal strength cooperate in the induction of CD40L in human and mouse CD8+ T cells[J]. Eur J Immunol,2013,43(6):1511- 1517.
|
| [10] |
Venet F, Monneret G. Advances in the understanding and treatment of sepsis-induced immunosuppression[J]. Nat Rev Nephrol,2018,14(2):121-137.
|
| [11] |
Clere-Jehl R, Mariotte A, Meziani F, et al. JAK-STAT targeting offers novel therapeutic opportunities in sepsis[J]. Trends Mol Med,2020,26(11):987-1002.
|
| [12] |
Bosmann M, Strobl B, Kichler N, et al. Tyrosine kinase 2 promotes sepsis-associated lethality by facilitating production of interleukin-27[J]. J Leukocyte Biol,2014,96(1):123-131.
|
| [13] |
Hillmer EJ, Zhang HY, Li HS, et al. Stat3 signaling in immunity[J]. Cytokine Growth Factor Rev,2016,31:1-15.
|
| [14] |
Eddy WE, Gong KQ, Bell B, et al. Stat5 is required for CD103(+) dendritic cell and alveolar macrophage development and protection from lung injury[J]. J Immunol,2017,198(12):4813-4822.
|
| [15] |
Horhold F, Eisel D, Oswald M, et al. Reprogramming of macrophages employing gene regulatory and metabolic network models[J]. PLoS Comput Biol,2020,16(2):e1007657.
|
| [16] |
Zhang S, Liu X, Goldstein S, et al. Role of the JAK/STAT signaling pathway in the pathogenesis of acute myocardial infarction in rats and its effect on NF-kappa B expression[J]. Mol Med Rep,2013,7(1):93-98.
|
| [17] |
Karki R, Kanneganti TD. The 'cytokine storm’: Molecular mechanisms and therapeutic prospects[J]. Trends Immunol,2021,42(8):681-705.
|
| [18] |
Li T, Wu S, Zhang H, et al. Activation of nicotinic receptors inhibits TNF-α-induced production of pro-inflammatory mediators through the jak2/stat3 signaling pathway in fibroblast-like synoviocytes[J]. Inflammation,2015,38(4):1424-1433.
|
| [19] |
Banerjee S, Biehl A, Gadina M, et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: Current and future prospects[J]. Drugs,2017,77(5):521-546.
|
| [20] |
Xu WL, Li SL, Li M, et al. Targeted elimination of myeloid-derived suppressor cells via regulation of the STAT pathway alleviates tumor immunosuppression in neuroblastoma[J]. Immunol Lett,2021,240:31-40.
|
| [21] |
孔雅娴，栗雅杰，马雅銮, 等. 小鼠腹腔持续置管引流模型骨髓髓系造血受抑制的研究[J/CD]. 中华实验和临床感染病杂志(电子版),2014,8(4):453-457.
|
| [22] |
Van Egeren D, Escabi J, Nguyen M, et al. Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms[J]. Cell Stem Cell,2021,28(3):514-523. e9.
|
| [23] |
尹江宁，殷雪平，陈义坤, 等. 重组人白细胞介素-11对脓毒症大鼠肺损伤的保护作用[J]. 中国急救医学,2020,40(2):164-169.
|
| [24] |
智鹏，杨波，陈浩然, 等. Α干扰素抗病毒相关全基因组表达谱的生物信息学分析及其对新型冠状病毒肺炎潜在药物研究的意义[J]. 转化医学杂志,2020,9(6):368-372.
|
| [25] |
Zhang C, Wu Z, Li JW, et al. Cytokine release syndrome in severe COVID-19: Interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality[J]. Int J Antimicrob Agents,2020,55(5):105954.
|
| [26] |
Luo Y, Alexander M, Gadina M, et al. JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition[J]. J Allergy Clin Immunol,2021,148(4):911-925.
|
| [27] |
Ferrao R, Wallweber HJA, Ho H, et al. The structural basis for class ii cytokine receptor recognition by JAK1[J]. Structure,2016,24(6):897- 905.
|
| [28] |
Ansari MJ, Alshahrani SM. Nano-encapsulation and characterization of baricitinib using poly-lactic-glycolic acid co-polymer[J]. Saudi Med J,2019,27(4):491-501.
|
| [29] |
De Vries LCS, Duarte JM, De Krijger M, et al. A JAK1 selective kinase inhibitor and tofacitinib affect macrophage activation and function[J]. Inflamm Bowel Dis,2019,25(4):647-660.
|